Innocare Pharma
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 24 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China, reported total carbon emissions of approximately 12,134,540 kg CO2e for the year 2023. This figure includes about 19,950 kg CO2e from Scope 1 emissions and approximately 12,114,590 kg CO2e from Scope 2 emissions. The company has shown a significant increase in emissions compared to 2022, when total emissions were about 9,835,800 kg CO2e, all from Scope 2, as there were no Scope 1 emissions recorded that year. In 2021, Innocare Pharma's emissions were approximately 9,236,400 kg CO2e, again solely from Scope 2. The emissions for 2020 were about 2,476,590 kg CO2e, also entirely from Scope 2. This trend indicates a growing operational footprint, particularly in Scope 2 emissions, which are primarily associated with purchased electricity. Despite the increase in emissions, Innocare Pharma has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s climate strategy appears to be in its early stages, with no significant pledges or initiatives reported to date. Overall, Innocare Pharma's emissions data reflects a reliance on electricity consumption, highlighting the need for a comprehensive climate strategy to address its carbon footprint effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innocare Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
